Niki BioSolutions, Inc.: financing cash flow
Financing cash flow for Niki BioSolutions, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Niki BioSolutions, Inc. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-03-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 4,415,199 | USD | 2026-03-27 | 20-F · 0001213900-26-035484 |
| 2023-01-01 | 2023-12-31 | 4,092,068 | USD | 2026-03-27 | 20-F · 0001213900-26-035484 |
| 2022-01-01 | 2022-12-31 | 6,625,462 | USD | 2025-04-30 | 20-F · 0001213900-25-037669 |
| 2021-01-01 | 2021-12-31 | 2,780,725 | USD | 2024-04-30 | 20-F · 0001213900-24-037520 |
| 2020-01-01 | 2020-12-31 | 12,421,932 | USD | 2023-04-28 | 20-F · 0001213900-23-033525 |
| 2019-01-01 | 2019-12-31 | -7,323,371 | USD | 2023-01-17 | 20-F/A · 0001213900-23-002916 |
| 2018-01-01 | 2018-12-31 | 25,478,949 | USD | 2021-04-19 | 20-F · 0001213900-21-021984 |
| 2017-03-01 | 2017-12-31 | 9,082,001 | USD | 2020-04-29 | 20-F · 0001213900-20-010347 |
Related financial histories
- Niki BioSolutions, Inc.: total assets
- Niki BioSolutions, Inc.: total liabilities
- Niki BioSolutions, Inc.: stockholders equity
- Niki BioSolutions, Inc.: cash and cash equivalents
- Niki BioSolutions, Inc.: net income or loss
- Niki BioSolutions, Inc.: operating cash flow
- Niki BioSolutions, Inc.: capital expenditure payments
- Niki BioSolutions, Inc.: revenue
- Niki BioSolutions, Inc.: investing cash flow
- Niki BioSolutions, Inc.: retained earnings or deficit
- Niki BioSolutions, Inc.: basic weighted-average shares
- Niki BioSolutions, Inc.: diluted weighted-average shares
- Niki BioSolutions, Inc.: basic earnings per share
- Niki BioSolutions, Inc.: diluted earnings per share
- Niki BioSolutions, Inc.: net property, plant and equipment
- Niki BioSolutions, Inc.: share-based compensation expense
- Niki BioSolutions, Inc.: current assets
- Niki BioSolutions, Inc.: current liabilities
- Niki BioSolutions, Inc.: net finite-lived intangible assets
- Niki BioSolutions, Inc.: net current accounts receivable
- Niki BioSolutions, Inc.: operating expenses
- Niki BioSolutions, Inc.: net inventory
- Niki BioSolutions, Inc.: cost of revenue
- Niki BioSolutions, Inc.: research and development expense
Inspect the source
- Entity
- Niki BioSolutions, Inc. / CIK 0001734005
- Captured
- 2026-09-21T17:25:26.957Z
- SEC response SHA-256
f34238bceb73cca1adaefab8f58fd2e934415f294cf76da9d5479015a6447310
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001734005.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))